WO2005002420A2 - Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma - Google Patents
Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma Download PDFInfo
- Publication number
- WO2005002420A2 WO2005002420A2 PCT/US2004/019633 US2004019633W WO2005002420A2 WO 2005002420 A2 WO2005002420 A2 WO 2005002420A2 US 2004019633 W US2004019633 W US 2004019633W WO 2005002420 A2 WO2005002420 A2 WO 2005002420A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- visual
- patient
- glaucoma
- evoked potential
- recording
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/377—Electroencephalography [EEG] using evoked responses
- A61B5/378—Visual stimuli
Definitions
- the present invention relates to the field of medical diagnosis and monitoring.
- Glaucoma in particular, primary open-angle glaucoma is one of the leading causes of blindness in the United States (Prevent Blindness America and the National Eye Institute, 2002). It produces a gradual and progressive degeneration of retinal ganglion cells, which transmit visual information along the optic nerve to the brain. Unfortunately, by the time this glaucomatous neuropathy is detected, there is typically extensive and permanent damage to the visual system and profound loss in visual function. There is evidence to indicate that select pathways of the visual system are affected in an early stage of the disease. Although glaucoma is often associated with elevated intraocular pressure, this is not always the case.
- the retina of the eye contains more than 130 million light-sensitive cells. These cells convert light into neural signals that are processed by a variety of neurons for certain features, and then transmitted via the optic nerve to the brain for interpretation.
- birth defects, trauma from accidents, numerous kinds of disease, and age-related deterioration of the components of the eye can all contribute to visual disorders.
- Information processing in the brain is electrochemical in nature. Evoked potentials are the electrical responses of the brain elicited by sensory stimulation. The electrical responses of the brain produced by visual stimulation are visual evoked potentials.
- Alterations in the characteristic visual evoked potential indicate anomalies along the visual pathways.
- the visual evoked potential is measured from the scalp via surface electrodes while visual stimuli are displayed on a video monitor placed in front of the patient.
- a corresponding brain potential is evoked at an information-processing part of the brain that functions to manage that particular sense.
- Visual evoked potentials can be used for diagnostic testing to assist physicians in the diagnosis of brain damage, diseases of the central nervous system, and diseases of the visual system in particular.
- the visual evoked potential (VEP) is a noninvasive measure of cortical activity elicited by a visual stimulus.
- ON and OFF cells originate at the first synapse in the retina, and they mediate the distinct perceptions of brightness (positive contrast) and darkness (negative contrast), respectively (Schiller, Sandell, & Maunsell, 1986).
- the ON pathway is particularly sensitive to disease processes involved in congenital stationary night blindness, muscular dystrophy, and glaucoma (Badr et al., 2003; Benoff et al., 2001; Fitzgerald et al., 1994; Greenstein et al., 1998).
- LGN lateral geniculate nucleus
- step 202 the user needs to configure the stimulus for parameters (e.g., spatial patterns, temporal frequency, contrast, luminance, number of repeated tests, etc.), and save the stimulus configuration in the system's computer.
- step 204 a user enters the patient's information.
- the user needs to select the pre-configured stimulus and the VEP data acquisition parameters (e.g., sampling rate in terms of the stimulus frequency and the frequency components in the VEP of interest to be extracted), at step 206.
- the computer performs the test by displaying a stimulus to a patient and recording a VEP signal.
- step 210 the computer saves VEP raw data to a hard disk.
- step 212 the user has to determine if the test is complete. If the answer is no, the procedure goes back to step 206. If the answer is yes, then at step 214 (not automatically following step 212), the user has to take the stored VEP raw data and process the data with custom-made software to perform an assessment of visual function.
- the present invention provides a system and method for automated, electrophysiological assessment of visual function in glaucoma suspects and patients using visual evoked potentials measured in response to periodic stimuli presented to the patients.
- a novel approach to stimulation and data processing are introduced to separate in a rapid and automated manner the contributions to the VEP response from the ON subdivision of the magnocellular pathway, which is sensitive to early-stage glaucomatous neuropathy (Greenstein et al., 1998).
- the processed VEP result is compared with a preset critical value to indicate the likelihood of the patient's glaucoma status - high (positive) or low (negative) with a certain confidence level.
- the present invention is directed to the design of a system and method for performing an automated neurophysiological test for the detection and monitoring of early- stage glaucoma. It includes the generation and display of a periodic visual stimulus, presented several times, for observation by a patient, and the measurement of the patient's visual evoked potential (VEP) in response to the visual stimulus.
- VEP visual evoked potential
- the VEP data elicited by each stimulus displayed, is recorded and stored, and then processed with a digital Fourier 2 transform (DFT) and analyzed with T circle statistical methods (Victor & Mast, 1991).
- DFT digital Fourier 2 transform
- the configuration of the stimulus, data collection, and data processing parameters is a complicated process in the prior art. It requires a significant learning period for a new user, and it relies heavily on a user's previous experience with the prior art machine and expertise in the VEP field. Thus, the test result depends greatly on the user.
- the prior art system does not provide an objective measure. The user must perform extensive analysis on the raw data with custom-made software to yield a product that is interpretable. Thus, the prior art system is serviceable for only a handful of professionals with a high degree of specialized knowledge in this field.
- the present invention in one embodiment provides a method comprising the steps of entering a patient's information into a computer, initializing a visual stimulus for the patient, recording a plurality of visual evoked potential signals obtained from one or more electrodes attached to the patient's scalp, saving data relating to the visual evoked potential signals, and determining if the likelihood of glaucoma is high or low based on the data.
- the method may further include performing a discrete Fourier transform on the saved data, performing a multivariate statistical method to determine a signal-to-noise ratio for the data, determining a critical signal-to-noise value, and comparing the signal-to-noise ratio with the critical value and determining if the likelihood of glaucoma is high or low based on the comparison.
- the method may also include displaying an indication of whether there is a high or low likelihood of glaucoma on a computer monitor.
- the multivariate statistical method applied may be a 2 T circle method.
- an apparatus comprising a computer processor and a computer memory.
- the computer processor may be programmed by computer software to receive a patient's information (e.g., ID number, gender, date of birth, etc.) initialize a visual stimulus for the patient, record a plurality of visual evoked potential signals obtained from one or more electrodes attached to the patient's scalp, save data relating to the visual evoked potential signals to the computer memory, and determine if a likelihood of glaucoma is high or low based on the data.
- a patient's information e.g., ID number, gender, date of birth, etc.
- the computer processor may be programmed to perform a discrete Fourier transform on the saved data, perform a multivariate statistical computation to determine a signal-to-noise ratio for the data, and to compare the signal-to-noise ratio with a preset critical signal-to-noise value to determine if the likelihood of glaucoma is high or low based on the comparison.
- the apparatus in at least one embodiment may be comprised of a computer monitor; wherein the computer processor may be programmed to display an indication of whether there is a high or low likelihood of glaucoma on the computer monitor.
- the apparatus is also comprised of a VEP recording and measuring device that amplifies the VEP signals picked up by the surface electrodes and converts these analog signals to digital signals which are then fed into the computer processor.
- Figure 1 is a block diagram illustrating the overall architecture of an embodiment of the present invention
- Figure 2 illustrates an isolated-check stimulus and a uniform-field stimulus used in an embodiment of the present invention
- Figure 3 shows a flow chart of a prior art procedure and method used to conduct studies on early-stage glaucoma
- Figure 4 shows a flow chart of a method in accordance with an embodiment of the current invention for evaluation of neural deficits in glaucoma suspects and patients;
- Figure 5 demonstrates a test result for glaucoma assessment of an embodiment of the current invention for one eye.
- FIG 1 is a block diagram of an apparatus 10 of an overall architecture of an embodiment of the present invention.
- the apparatus 10 includes a computer processor 12, a VEP recording and measuring device 14, a visual stimulus generating device 16, a computer monitor 20, an interactive device 22, and a memory 24.
- the interactive device 22 may be a computer mouse and/or a keyboard or other input device.
- the memory 24 may be any type of computer memory.
- the computer monitor 20 may be a typical computer display monitor.
- the computer processor 12 is electrically connected by a communications bus (e.g., PCI (Peripheral Component Interconnect)) 12b to a visual stimulus generating device 16 and by a communications bus (e.g., PCI, USB (Universal Serial Bus), etc.) 12a to a VEP recording and measuring device 14.
- the VEP recording and measuring device 14 is electrically connected by communications lines 14a, 14b, and 14c to electrodes 15a, 15b, and 15c.
- the electrodes 15a, 15b, and 15c are attached to the head 18 of a person or patient 17.
- the computer processor 12 is electrically connected by communications lines 12c, 12d, and 12e, to the computer monitor 20, interactive device 22, and the memory 24, respectively.
- the computer processor 12 may be a computer processor for a typical personal computer.
- the computer processor 12 typically controls the operation of both the VEP recording and measuring device 14 for data acquisition and the visual stimulus-generating device 16 for stimulus display.
- the VEP recording and measuring device 14 typically includes an amplifier to enhance VEP signals being acquired via communications lines 14a, 14b, or 14c, and an A/D (analog to digital) converter to convert the VEP analog signals to digital signals which are sent via communications bus12a to the computer processor 12 for processing.
- the amplifier of the VEP recording and measuring device 14 optically isolates patients, such as patient 17, from the electrical source, such as a power source for the device 14, for safety.
- the amplifier of device 14 has a high common mode rejection ratio, low noise and high stability for low VEP signal operation.
- the amplifier also has a band-pass filter to reject the low-frequency drift and high-frequency noise beyond the bandwidth.
- the visual stimulus-generating device 16 typically includes a video display monitor and a graphics card, and is connected to and controlled by the computer processor 12, for generating visual stimuli on the display screen 16a to be viewed by patients, such as the patient 17 in Figure 1.
- the neural responses such as neural response from head 18 to the stimuli are picked up by the sensory electrodes 15a, 15b, and 15c, attached non-invasively to the patient's scalp 18 and are amplified, recorded and digitized in the VEP recording and measuring device 14 as is known in the art.
- the electrodes are positioned on the scalp 18 of the patient over the visual cortex (active electrode 15a to receive the VEP), the middle of the forehead (reference electrode 15c), and the right side of the forehead (floating ground electrode 15b). This arrangement of attachment of electrodes is known in the art. Electrodes 15a-15c are connected by communications lines 14a, 14b, and 14c, which are typically hardwires, to the VEP recording and measuring device 14.
- the interactive device 22 provides a means to input information to the computer 12 regarding the patient 17 being tested (e.g., ID number, gender, date of birth, etc.).
- the operator's computer monitor 20 displays the information entered via the interactive device 22, an operation menu for instruction selection, as well as test results as demonstrated in Figure 5.
- Figure 2 illustrates an isolated-check pattern 100 and a uniform field 110.
- the pattern 100 and the field 110 may be displayed alternatively in a periodic manner at a frequency of approximately twelve Hertz by the visual stimulus-generating device 16.
- 32x32 isolated-checks squares
- the background luminance such as for background 102 and background 112 for both pattern 100 and uniform field 110, respectively, is typically (known in the art) 100 nits (cd/m2).
- the luminance of the checks, such as, check 102a is 8% higher than that of the background, such as background 102 (108 nits), which has been shown to be the critical stimulus condition for the detection of glaucomatous damage.
- Patients, such as patient 17 in Figure 1 typically view a stimulus, such as either 100 or 110 in Figure 2, with a physical image size of 20 cm (centimeters) x 20 cm (centimeters) at a distance of one hundred and fifteen centimeters.
- Figure 4 shows a flow chart 300 of a method of one embodiment of the current invention with an automated procedure and a method for evaluation of neural deficits in glaucoma suspects and patients.
- a user enters a patient's information, such as information for patient 17, into computer processor 12 via the interactive device 22.
- the computer processor 12 initializes a stimulus by loading specific pattern images 100, 110 into the stimulus-generating device 16.
- the computer processor 12 performs a test by timely controlling the stimulus-generating device 16 and VEP recording and measuring device 14 to display the stimulus to the patient 17 and to record the VEP signal through the recording and measuring device 14.
- the computer processor 12 saves the VEP raw data to the memory 24.
- the computer processor 12 determines if the test is complete. If the answer is no, then the procedure goes back to step 306. If the answer is yes then the procedure next executes step 312.
- the computer processor 12 2 performs a discrete Fourier transform and T circle statistics on the saved VEP raw data.
- step 314 the computer processor 12 compares the signal-to-noise ratio (SNR) with a preset critical value and generates a result - likelihood of glaucoma: high or low.
- step 316 the computer processor 12 displays the result - likelihood of glaucoma high or low, such as through a text message, on the computer monitor 20.
- SNR signal-to-noise ratio
- the present invention in one or more embodiments incorporates computer software contained in the computer processor 12 for displaying a graphical user interface (GUI) on the operator's monitor 20 upon initiation of a testing procedure.
- GUI graphical user interface
- the GUI allows an operator to enter patient data into the computer processor 12 (via the interactive device 22) such as date of birth, identification number, etc.
- the computer processor 12 will initialize the stimulus patterns by loading the images into the stimulus-generating device 16 at step 304.
- the test will begin with the presentation of the visual stimulus on the stimulus display screen 16a for observation by the patient 17 and data recording by the recording and measuring device 14, both are timely controlled by the computer processor 12.
- the stimulus may be comprised of both of the two visual images 100 and 110 depicted in Figure 2 that alternate with a frequency of about twelve Hertz.
- the stimulus will typically be displayed for about five seconds.
- a set of five to ten of these stimuli will typically be presented to the patient 17 for observation by each eye of the patient 17.
- the recording device 14 will relay the recorded data to the computer processor 12 for saving the data into the memory 24.
- the number of stimulus presentations completed / data epochs collected is compared by the software program to the preset number (five or ten) to determine if the test is complete at step 310.
- the Fourier component of the VEP (amplitude and phase values) at the fundamental (stimulus) frequency (-twelve Hertz) will be calculated by the computer processor 12.
- the mean Fourier component from the five to ten repeated samples obtained from stimulation of 2 each eye will also be calculated.
- a multivariate statistical method (T circle > Victor & Mast,
- the signal-to-noise ratio is defined as the ratio of the mean amplitude of the fundamental Fourier component to the radius of the noise circle.
- Figure 5 illustrates an example of a hypothetical test for one eye.
- the current system of one embodiment of the present invention will compare the SNR with a critical SNR value based on previous results from glaucoma research studies (e.g., Greenstein et al., 1998; Badr et al., 2003) to yield a decision - likelihood of glaucoma is high if the SNR is less than the critical value, or low if the SNR is equal to or greater than the critical value.
- the critical value may be a fixed value in one embodiment of the current invention (e.g., set to a value of 1).
- the current system of one embodiment of the present invention will display the status of the result for each eye tested on the computer monitor 20 immediately following the test done.
- One aspect of the present invention is an apparatus that provides an objective, non- invasive and automated procedure for evaluation of early-stage glaucomatous damage. It integrates the following features: 1) novel stimulus technique, depicted in Figure 2, that is designed to drive selectively the parallel pathway of interest (ON subdivision of the magnocellular pathway), which is known to be affected in the early stages of glaucomatous 2 neuropathy; 2) discrete Fourier transform followed by application of the T circle statistical
- Figure 5 demonstrates a chart 400 of test results for glaucoma diagnosis for one eye.
- the y-axis 402 is for the sine coefficient of the fundamental frequency component of the VEP obtained through Fourier analysis, and the x-axis 404 is for the corresponding cosine coefficient of this component.
- the "+" symbols, such as 406a are individual estimates of the fundamental component derived from each VEP epoch (five to ten epochs per test of each eye), the dot symbol 406b represents the mean of all of the fundamental component estimates such as 406a.
- the circle 408 represents the "error circle” - a 95% 2 confidence region established with the T circle statistic.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pathology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04755672A EP1643896A4 (en) | 2003-06-27 | 2004-06-16 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
AU2004253483A AU2004253483B2 (en) | 2003-06-27 | 2004-06-16 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
JP2006517445A JP2007524448A (en) | 2003-06-27 | 2004-06-16 | Automatic treatment method and apparatus for detecting and monitoring early glaucoma |
CA002530071A CA2530071A1 (en) | 2003-06-27 | 2004-06-16 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
IL172725A IL172725A (en) | 2004-06-16 | 2005-12-21 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/608,627 US6966650B2 (en) | 2003-06-27 | 2003-06-27 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
US10/608,627 | 2003-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005002420A2 true WO2005002420A2 (en) | 2005-01-13 |
WO2005002420A3 WO2005002420A3 (en) | 2005-05-12 |
Family
ID=33540626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/019633 WO2005002420A2 (en) | 2003-06-27 | 2004-06-16 | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma |
Country Status (7)
Country | Link |
---|---|
US (1) | US6966650B2 (en) |
EP (1) | EP1643896A4 (en) |
JP (1) | JP2007524448A (en) |
CN (1) | CN100450429C (en) |
AU (1) | AU2004253483B2 (en) |
CA (1) | CA2530071A1 (en) |
WO (1) | WO2005002420A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210312613A1 (en) * | 2020-04-03 | 2021-10-07 | Wisconsin Alumni Research Foundation | Apparatus for Detection of Early-Stage Glaucoma and Other Optic Nerve Diseases |
US11357442B2 (en) | 2015-05-12 | 2022-06-14 | Diagnosys LLC | Combined stimulator and electrode assembly for mouse electroretinography (ERG) |
US11497911B2 (en) | 2018-07-18 | 2022-11-15 | Diagnosys LLC | Electrically evoked response (EER) stimulator/amplifier combination |
US12076154B2 (en) | 2015-11-10 | 2024-09-03 | Diagnosys LLC | Method and apparatus for the assessment of electrophysiological signals |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ521952A (en) * | 2000-04-17 | 2004-03-26 | Stuart Graham | Method and apparatus for electrophysiological assessment of visual function using a head-mounted stereo display |
EP1989998B1 (en) * | 2001-06-13 | 2014-03-12 | Compumedics Medical Innovation Pty Ltd. | Methods and apparatus for monitoring consciousness |
US7578795B2 (en) * | 2001-08-07 | 2009-08-25 | Diopsys, Inc. | System and method for vision examination utilizing fault detection |
US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
US8083350B2 (en) * | 2005-11-21 | 2011-12-27 | The Curators Of The University Of Missouri | Light sensitivity meter and uses thereof |
US8083354B2 (en) * | 2007-10-03 | 2011-12-27 | Diopsys, Inc. | Simultaneously multi-temporal visual test and method and apparatus therefor |
EP2217133B1 (en) * | 2007-11-09 | 2017-12-20 | The Australian National University | Method and apparatus for visual sensory field assessment |
GB2467710B (en) * | 2007-11-16 | 2013-02-20 | San Diego State University Res Foundation | Methods for treating social disorders |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US20100312145A1 (en) * | 2008-02-22 | 2010-12-09 | Arneborg Ernst | Device for the functional diagnosis of vestibular reflex arcs using myogenic potentials |
US8888288B2 (en) | 2011-02-23 | 2014-11-18 | Nikoo Iravani | Method and system for self-administering a visual examination using a mobile computing device |
CN102789441B (en) * | 2012-08-09 | 2015-03-18 | 上海海事大学 | Asynchronous brain-computer interface system based on steady state evoked potential and method for realizing asynchronous brain-computer interface system |
CN106308738B (en) * | 2016-08-30 | 2018-02-16 | 湖州美科沃华医疗技术有限公司 | A kind of device and method for glaucoma detection |
US11109795B2 (en) * | 2018-07-27 | 2021-09-07 | Ronald Siwoff | Device and method for measuring and displaying bioelectrical function of the eyes and brain |
US10827922B2 (en) * | 2018-10-22 | 2020-11-10 | Zongqi Hu | Apparatus and method for objective visual acuity measurement using dynamic velocity threshold filter in optokinetic response processing |
FI129056B (en) * | 2019-05-31 | 2021-06-15 | Aalto Univ Foundation Sr | A method and device for determining changes in retinal and/or brain temperature |
CN110464298B (en) * | 2019-07-25 | 2021-11-02 | 深圳大学 | Electroencephalogram signal processing device and method |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634243A (en) * | 1984-12-26 | 1987-01-06 | Lkc Systems, Inc. | Glaucoma detection utilizing pattern discrimination test |
JPH0657202B2 (en) * | 1986-10-03 | 1994-08-03 | 里子 佐藤 | EEG recording device |
US5065767A (en) * | 1988-08-26 | 1991-11-19 | The Australian National University | Method for use in diagnosis of glaucoma |
US5176147A (en) * | 1990-04-29 | 1993-01-05 | Bodis Wollner Ivan G | Method and apparatus for detecting optic neuropathy |
US5539482A (en) * | 1992-02-28 | 1996-07-23 | The Australian National University | Glaucoma testing using non-linear systems identification techniques |
JP2508946B2 (en) * | 1992-06-05 | 1996-06-19 | 日本電気株式会社 | In-vivo equivalent current dipole localization device |
AUPM537994A0 (en) * | 1994-04-29 | 1994-05-26 | Australian National University, The | Early detection of glaucoma |
US6477407B1 (en) * | 1998-05-08 | 2002-11-05 | The University Of Sydney | Electrophysiological visual field measurement |
EP1139855B1 (en) * | 1998-12-30 | 2008-08-27 | HEIJL, Anders | A method and an apparatus for performing a visual field test, and computer programs for processing the results thereof |
WO2001039659A1 (en) * | 1999-12-03 | 2001-06-07 | Iouri Malov | Field testing using spread spectrum technique |
NZ521952A (en) * | 2000-04-17 | 2004-03-26 | Stuart Graham | Method and apparatus for electrophysiological assessment of visual function using a head-mounted stereo display |
US7578795B2 (en) * | 2001-08-07 | 2009-08-25 | Diopsys, Inc. | System and method for vision examination utilizing fault detection |
-
2003
- 2003-06-27 US US10/608,627 patent/US6966650B2/en not_active Expired - Lifetime
-
2004
- 2004-06-16 JP JP2006517445A patent/JP2007524448A/en active Pending
- 2004-06-16 EP EP04755672A patent/EP1643896A4/en not_active Withdrawn
- 2004-06-16 AU AU2004253483A patent/AU2004253483B2/en not_active Ceased
- 2004-06-16 CN CNB2004800217484A patent/CN100450429C/en not_active Expired - Fee Related
- 2004-06-16 CA CA002530071A patent/CA2530071A1/en not_active Abandoned
- 2004-06-16 WO PCT/US2004/019633 patent/WO2005002420A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP1643896A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11357442B2 (en) | 2015-05-12 | 2022-06-14 | Diagnosys LLC | Combined stimulator and electrode assembly for mouse electroretinography (ERG) |
US12076154B2 (en) | 2015-11-10 | 2024-09-03 | Diagnosys LLC | Method and apparatus for the assessment of electrophysiological signals |
US11497911B2 (en) | 2018-07-18 | 2022-11-15 | Diagnosys LLC | Electrically evoked response (EER) stimulator/amplifier combination |
US20210312613A1 (en) * | 2020-04-03 | 2021-10-07 | Wisconsin Alumni Research Foundation | Apparatus for Detection of Early-Stage Glaucoma and Other Optic Nerve Diseases |
US11651486B2 (en) * | 2020-04-03 | 2023-05-16 | Wisconsin Alumni Research Foundation | Apparatus for detection of early-stage glaucoma and other optic nerve diseases |
Also Published As
Publication number | Publication date |
---|---|
CN100450429C (en) | 2009-01-14 |
EP1643896A4 (en) | 2009-01-21 |
WO2005002420A3 (en) | 2005-05-12 |
JP2007524448A (en) | 2007-08-30 |
AU2004253483A1 (en) | 2005-01-13 |
EP1643896A2 (en) | 2006-04-12 |
AU2004253483B2 (en) | 2008-07-03 |
CN1829469A (en) | 2006-09-06 |
CA2530071A1 (en) | 2005-01-13 |
US6966650B2 (en) | 2005-11-22 |
US20040263780A1 (en) | 2004-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004253483B2 (en) | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma | |
US20210052182A1 (en) | Portable brain activity sensing platform for assessment of visual field deficits | |
JP5476137B2 (en) | Human interface based on biological and brain function measurement | |
CN110801237A (en) | Cognitive ability assessment system and method based on eye movement and electroencephalogram characteristics | |
US20060282008A1 (en) | System and method for vision examination utilizing fault detection | |
US6475162B1 (en) | System and method for vision examination using interrupt signals for synchronizing visual evoked potential sampling rate with visual stimulus | |
CN109069081A (en) | For predicting, screening and monitoring encephalopathy/delirium equipment, system and method | |
CN113288174B (en) | Method for detecting cognitive function of schizophrenic patient | |
Manjur et al. | Spectral analysis of Electroretinography to differentiate autism spectrum disorder and attention deficit hyperactivity disorder. | |
CN107296586A (en) | Collimation error detection device/method and writing system/method based on the equipment | |
CN110664402A (en) | Signal data extraction method and device | |
IL172725A (en) | Method and apparatus for an automated procedure to detect and monitor early-stage glaucoma | |
US10667714B2 (en) | Method and system for detecting information of brain-heart connectivity by using pupillary variation | |
CN117918856B (en) | INPH prediction method and iNPH prediction equipment based on new and old stimulation BCI paradigm | |
Freyer | Data pre-processing and feature analysis for a feature-based EEG alcohol detector | |
You et al. | Similarities and differences between chronic primary pain and depression in brain activities: Evidence from resting-state microstates and auditory Oddball task | |
Pandey et al. | The Electroretinogram in Clinical Practice: A Comprehensive Review | |
Suman et al. | Automatic Detection of Genetic Diseases in Paediatric Age Using Pupillometry | |
WO2023230017A1 (en) | Determining brain health | |
Duffy et al. | Recommended Standards and Practices for Brain Electrical Activity Mapping and Topographic Analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480021748.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2530071 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 172725 Country of ref document: IL Ref document number: 2006517445 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004253483 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004755672 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11/DELNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004253483 Country of ref document: AU Date of ref document: 20040616 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004253483 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004755672 Country of ref document: EP |